mupirocin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1857	12650-69-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: mupirocin mupricin pseudomonic acid turixin mupirocin calcium bactroban BRL 4910A	A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing. Molecular weight: 500.63 Formula: C26H44O9 CLOGP: 1.54 LIPINSKI: 1 HAC: 9 HDO: 4 TPSA: 146.05 ALOGS: -4.28 ROTB: 17 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

mupirocin
mupricin
pseudomonic acid
turixin
mupirocin calcium
bactroban
BRL 4910A

A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.

Molecular weight: 500.63
Formula: C26H44O9
CLOGP: 1.54
LIPINSKI: 1
HAC: 9
HDO: 4
TPSA: 146.05
ALOGS: -4.28
ROTB: 17

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Dec. 31, 1987	FDA	GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	40.19	13.35	23	10218	7182	46668639
Purpura senile	37.21	13.35	11	10230	624	46675197
Nasal vestibulitis	35.99	13.35	6	10235	19	46675802
Tarsal tunnel syndrome	32.58	13.35	10	10231	645	46675176
Toxicity to various agents	30.39	13.35	5	10236	211761	46464060
Resorption bone increased	27.25	13.35	10	10231	1117	46674704
Vestibular disorder	25.38	13.35	10	10231	1356	46674465
Appetite disorder	24.65	13.35	15	10226	5239	46670582
Cellulitis	23.13	13.35	49	10192	70239	46605582
Thrombophlebitis superficial	22.75	13.35	14	10227	4989	46670832
Staphylococcal infection	22.28	13.35	33	10208	35738	46640083
Sinusitis	21.54	13.35	70	10171	129698	46546123
Skin warm	18.96	13.35	12	10229	4491	46671330
Hyperchlorhydria	18.95	13.35	8	10233	1294	46674527
Hospitalisation	18.37	13.35	42	10199	63343	46612478
Folate deficiency	16.82	13.35	8	10233	1710	46674111
Bronchial oedema	16.54	13.35	4	10237	104	46675717
Dystrophic calcification	16.43	13.35	4	10237	107	46675714
Dysphoria	16.32	13.35	11	10230	4578	46671243
Vertigo positional	16.31	13.35	9	10232	2621	46673200
Therapy interrupted	15.07	13.35	15	10226	10776	46665045
Skin infection	14.45	13.35	15	10226	11324	46664497
Arthropod bite	13.94	13.35	11	10230	5830	46669991
Malnutrition	13.49	13.35	16	10225	13987	46661834
Haemorrhagic diathesis	13.45	13.35	9	10232	3699	46672122

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nasal vestibulitis	50.06	15.75	8	6258	19	29946193
Food aversion	40.55	15.75	10	6256	297	29945915
Staphylococcal infection	36.55	15.75	38	6228	30186	29916026
Pain of skin	30.13	15.75	15	6251	3718	29942494
Toxicity to various agents	24.25	15.75	4	6262	177179	29769033
Skin discolouration	23.04	15.75	22	6244	15772	29930440
Cellulitis	18.17	15.75	34	6232	46750	29899462
Cheilitis	18.01	15.75	9	6257	2247	29943965
Exercise tolerance decreased	16.09	15.75	10	6256	3802	29942410

Pharmacologic Action:

Source	Code	Description
ATC	D06AX09	DERMATOLOGICALS ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE ANTIBIOTICS FOR TOPICAL USE Other antibiotics for topical use
ATC	R01AX06	RESPIRATORY SYSTEM NASAL PREPARATIONS DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Other nasal preparations
FDA EPC	N0000175515	RNULL Synthetase Inhibitor Antibacterial
FDA MoA	N0000175516	RNULL Synthetase Inhibitors
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D011500	Protein Synthesis Inhibitors
CHEBI has role	CHEBI:36047	antibacterial drugs
CHEBI has role	CHEBI:48001	protein synthesis inhibitors
CHEBI has role	CHEBI:35441	anti-infective drugs

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Impetigo	indication	48277006	DOID:8504
Staph Aureus Traumatic Skin Lesion Infection	indication
Methicillin-Resistant Staphylococcus Aureus Nasal Colonization	indication
Traumatic Skin Lesion Streptococcus Pyogenes Infection	indication
Folliculitis	off-label use	13600006	DOID:4409
Atopic dermatitis	off-label use	24079001	DOID:3310
Eczema	off-label use	43116000
Epidermolysis bullosa	off-label use	61003004	DOID:2730
Ecthyma	off-label use	85791004
Furunculosis	off-label use	112650006
Minor Bacterial Skin Infections	off-label use
Skin irritation	contraindication	367466007

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.76	acidic
pKa2	12.42	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Isoleucine--tRNA ligase, cytoplasmic	Enzyme	P41252	SYIC_HUMAN		IC50	9.10	CHEMBL
Isoleucine--tRNA ligase	Enzyme		SYI1_STAAU	INHIBITOR			DRUGBANK	CHEMBL
Isoleucine--tRNA ligase	Enzyme		SYI_STRP1	INHIBITOR			CHEMBL	CHEMBL
Isoleucine--tRNA ligase	Enzyme		SYI_ECOLI				WOMBAT-PK

External reference:

ID	Source
4019345	VUID
N0000147519	NUI
D01076	KEGG_DRUG
115074-43-6	SECONDARY_CAS_RN
4019345	VANDF
4021018	VANDF
C0733863	UMLSCUI
CHEBI:7025	CHEBI
MRC	PDB_CHEM_ID
CHEMBL719	ChEMBL_ID
CHEMBL2068726	ChEMBL_ID
CHEMBL3989715	ChEMBL_ID
D016712	MESH_DESCRIPTOR_UI
446596	PUBCHEM_CID
DB00410	DRUGBANK_ID
10916	IUPHAR_LIGAND_ID
5276	INN_ID
D0GX863OA5	UNII
221128	RXNORM
198973	MMSL
47751	MMSL
5138	MMSL
5139	MMSL
720	MMSL
002802	NDDF
005869	NDDF
387397004	SNOMEDCT_US
441528009	SNOMEDCT_US
71453003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1010	OINTMENT	20 mg	TOPICAL	ANDA	23 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0352	OINTMENT	20 mg	TOPICAL	ANDA	23 sections
BACTROBAN	HUMAN PRESCRIPTION DRUG LABEL	1	16590-028	CREAM	20 mg	TOPICAL	NDA	22 sections
MUPIROCIN	HUMAN PRESCRIPTION DRUG LABEL	1	16590-158	OINTMENT	20 mg	TOPICAL	ANDA	16 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	16714-055	CREAM	20 mg	TOPICAL	ANDA	28 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0112	OINTMENT	20 mg	TOPICAL	ANDA	20 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	21695-188	OINTMENT	20 mg	TOPICAL	ANDA	19 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	42254-137	OINTMENT	20 mg	TOPICAL	ANDA	19 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	42254-229	OINTMENT	20 mg	TOPICAL	ANDA	20 sections
CENTANY	HUMAN PRESCRIPTION DRUG LABEL	1	43538-300	OINTMENT	20 mg	TOPICAL	NDA	26 sections
Centany AT	HUMAN PRESCRIPTION DRUG LABEL	1	43538-310	OINTMENT	20 mg	TOPICAL	NDA	26 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	45802-112	OINTMENT	20 mg	TOPICAL	ANDA	24 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	45865-722	OINTMENT	20 mg	TOPICAL	ANDA	20 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	49999-644	OINTMENT	20 mg	TOPICAL	ANDA	20 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1587	OINTMENT	20 mg	TOPICAL	ANDA	24 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4349	OINTMENT	20 mg	TOPICAL	ANDA	24 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4397	OINTMENT	20 mg	TOPICAL	ANDA	24 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	50268-568	OINTMENT	20 mg	TOPICAL	ANDA	25 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	50436-0112	OINTMENT	20 mg	TOPICAL	ANDA	24 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	50436-0180	OINTMENT	20 mg	TOPICAL	ANDA	22 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	50436-1010	OINTMENT	20 mg	TOPICAL	ANDA	23 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	51672-1312	OINTMENT	20 mg	TOPICAL	ANDA	25 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	51672-1370	CREAM	20 mg	TOPICAL	ANDA	28 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	52959-743	OINTMENT	20 mg	TOPICAL	ANDA	20 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	53002-9850	OINTMENT	20 mg	TOPICAL	ANDA	22 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	53002-9851	OINTMENT	20 mg	TOPICAL	ANDA	24 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	53002-9852	OINTMENT	20 mg	TOPICAL	ANDA	23 sections
BACTROBAN	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4325	OINTMENT	20 mg	TOPICAL	NDA	23 sections
Bactroban	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4642	CREAM	20 mg	TOPICAL	NDA	23 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4958	OINTMENT	20 mg	TOPICAL	ANDA	19 sections